All In Biotech

Drug Trial Radar · NCT06048133

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) During First-line Treatment of Advanced Biliary Tract Cancers (QUIC)

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

33

Planned (sponsor's estimate)

Start

Mar 8, 2024

Primary completion

Dec 2026

Study completion Jul 2027

Sponsor

Lead sponsor
Nataliya UbohaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Arcus Biosciences, Inc.; Gilead Sciences; University of Wisconsin, Madison
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will include a safety run-in involving 6 study participants. The goal of the safety run-in is to screen for early safety signals of the proposed drug combination. Trial enrollment can continue while full safety assessment is being completed for the first 6 subjects. Participants will receive 4 cycles of combination therapy as described. After 4 cycles (\~6 months), cisplatin will be discontinued, while gemcitabine, zimberelimab (AB122), and quemliclustat (AB680) will be continued. Subjects will be treated until disease progression or development of intolerable toxicities. In total, there will be up to 39 participants on the study.

Conditions

  • Biliary Tract Carcinoma
  • Cholangiocarcinoma
  • Bile Duct Cancer

Interventions

  • GemcitabineDrug

    Gemcitabine IV: Day 1, 8, 22, and 29 every 42 days

  • CisplatinDrug

    Cisplatin IV: Day 1, 8, 22, and 29 every 42 days of Cycles 1-4 only.

  • ZimberelimabDrug

    Zimberelimab IV: Day 1 and 22 every 42 days

  • QuemliclustatDrug

    Quemliclustat IV: Day 1, 15, 29 every 42 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimate the progression free survival (PFS) with gemcitabine, cisplatin, quemliclustat (AB680) and zimberelimab (AB122) in patients with advanced BTCs.Time frame: 2 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • University of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.